New Hampshire 2023 Regular Session

New Hampshire House Bill HB610

Introduced
1/12/23  
Refer
1/12/23  
Report Pass
2/16/23  
Engrossed
3/7/23  
Refer
3/7/23  

Caption

Expanding the definition of providers who can certify patients of the therapeutic cannabis program and relative to release of a defendant pending trial and relative to product labeling and information guide requirements for cannabis products and the prohibition of the sale of hemp products containing certain levels of THC.

Impact

The implementation of HB610 is anticipated to refine existing state laws regarding the therapeutic use of cannabis. By facilitating a wider range of eligible healthcare providers, the bill may improve access for patients across New Hampshire. In addition, the adjustments to bail conditions aim to promote public safety and ensure that those charged with more serious offenses may be detained when deemed a risk to the public. The recuperation of the powers of the therapeutic cannabis oversight board to regulate product labeling and educational material will enhance consumer knowledge and safety.

Summary

House Bill 610 (HB610) aims to expand the definition of healthcare providers who can certify individuals for the therapeutic cannabis program in New Hampshire, allowing any licensed provider who can prescribe controlled substances to issue certifications. This bill is designed to facilitate access to cannabis for patients who may benefit from its therapeutic use, particularly minors, by establishing stricter guidelines that require dual certifications from healthcare providers, including at least one who specializes in pediatric care. Furthermore, the bill amends regulations surrounding bail conditions for defendants pending trial, establishing clearer parameters for their detention based on certain criminal offenses.

Sentiment

The general sentiment around HB610 appears to be supportive, particularly from advocates of expanded access to therapeutic cannabis. Proponents argue that by including more healthcare providers in the certification process, it removes barriers for patients, particularly those requiring pediatric care. However, there are concerns regarding the potential implications of the amendments related to bail conditions, with critics citing risks of increased detention duration without adequate legal representation for defendants. The balance between ensuring public safety and protecting individual rights is a recurring theme in the discourse surrounding this bill.

Contention

Notable points of contention include the dual certification requirement for minors, which some may view as unnecessarily stringent, potentially reducing access for young patients in need of therapeutic cannabis. Additionally, while aimed at enhancing safety and clarity, the provisions regarding bail may raise questions about due process and the rights of the accused. The prohibition on selling hemp products containing THC levels above a specified threshold is also likely to encounter resistance from hemp industry advocates who argue this could hinder economic opportunities in that sector.

Companion Bills

No companion bills found.

Previously Filed As

NH SB180

Relative to product labeling and information guide requirements for cannabis products and the prohibition of the sale of hemp products containing certain levels of THC.

NH SB180

Relative to product labeling and information guide requirements for cannabis products and the prohibition of the sale of hemp products containing certain levels of THC.

NH HB611

Relative to eligibility criteria for the therapeutic cannabis program and establishing a commission to study state-controlled sales of cannabis and relative to the prohibition on the sale of hemp products containing certain levels of THC.

NH SB357

Relative to expanding the definition of providers who can certify patients of the therapeutic cannabis program.

NH HB51

Relative to hemp-derived cannabinoids and the definition of cannabis in therapeutic cannabis.

NH HB272

Relative to the labeling and sale of hemp products containing CBD.

NH A1684

Directs Cannabis Regulatory Commission to adopt regulations concerning labeling, marketing, and sale of cannabidiol and products containing cannabidiol; prohibits sale of cannabidiol to minors.

NH A2436

Directs Cannabis Regulatory Commission to adopt regulations concerning labeling, marketing, and sale of cannabidiol and products containing cannabidiol; prohibits sale of cannabidiol to minors.

NH HB344

Relative to the home cultivation of cannabis plants and the possession of certain cannabis-infused products.

NH HB344

Relative to the home cultivation of cannabis plants and the possession of certain cannabis-infused products.

Similar Bills

ME LD137

An Act to Expand the 1998 Special Retirement Plan to Include Employees Who Work for the Office of Chief Medical Examiner

ME LD794

An Act to Include Judicial Marshals in the 1998 Special Plan for Retirement

ME LD610

An Act to Expand the 1998 Special Retirement Plan to Include Employees Who Work for the Office of Chief Medical Examiner

ME LD1761

An Act to Include Certain Mental Health Workers Under the 1998 Special Plan for Retirement

ME LD579

An Act to Include Certain Mental Health Workers Under the 1998 Special Plan for Retirement

ME LD1760

An Act to Include Certain Crisis Outreach and Crisis Services Workers Under the 1998 Special Plan for Retirement

IA HF182

A bill for an act relating to controlled substances, including certain controlled substances schedules and precursor substances reporting requirements, making penalties applicable, and including effective date provisions. (Formerly HSB 25.) Effective date: 03/28/2025.

IA SF305

A bill for an act relating to controlled substances, including certain controlled substances schedules and precursor substances reporting requirements, making penalties applicable, and including effective date provisions.(Formerly SSB 1080.)